In recognition of the studies indicating elevated serum VEGF and endocan in patients with hypertension or type II DM [43,44], we compared the levels of these two biomarkers between NSCLC patients with and without the stated conditions, revealing no significant differences in either biomarker between the groups. This evidence concerns the gene VEGFA and hypertensive disorder.